Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for tough cancers

NCT ID NCT02734004

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see if the combination can shrink or stabilize tumors. About 264 participants are enrolled, and the study is no longer recruiting new patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (MEDI4736), olaparib, and bevacizumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

264 people

The number who actually took part.

Started

Mar 2016

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following: * Platinum sensitive relapsed small cell lung cancer (module 1) * gBRCAm HER2-negative metastatic breast cancer (module 2) * gBRCAm ovarian cancer (modules 3 and 5) * Metastatic or relapsed Gastric cancer (adenocarcinoma) (module 4) * gBRCAm negative ovarian cancer (modules 6 and 7) * At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging \[MRI\] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. * Male or female patients, age ≥18 years (≥19 years for South Korea) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Life expectancy ≥12 weeks * Adequate organ and marrow function * Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted. * Ability of patient to understand and the willingness to sign a written informed consent document prior to any protocol related procedures, including screening evaluations. * Female patients must either: * Be of non-reproductive potential OR * Have a negative serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1, and agree to use contraception if they or their partner are of reproductive potential Exclusion criteria * Prior chemotherapy or other systemic anticancer therapy within 4 weeks prior to start of olaparib treatment, 6 weeks for nitrosoureas or mitomycin. Exceptions include: Anti-hormonal treatment for ER positive or PR positive breast cancer is allowed until 7 days prior to treatment with olaparib, exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to start of olaparib treatment is not allowed, prior receipt of biologics targeting T cell co-regulatory proteins and/or immune checkpoints is not allowed. Examples include MEDI4736 or other PD1 or PD-L1 or PD-L2 inhibitors or anti-CTLA4 therapy, previous treatment with a PARP inhibitor, is not allowed. * Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start. * Current dependency on total parenteral nutrition or IV fluid hydration. * Concomitant use of known strong cytochrome P450 (CYP) 3A (CYP3A) inhibitors or moderate CYP3A inhibitors. Concomitant use of known strong or moderate CYP3A inducers. * Concomitant therapy with any other anticancer therapy or chronic use of systemic corticosteroids. * Previous allogenic bone marrow transplant or double umbilical cord blood transplantation * Whole blood transfusions in the last 120 days * Patients with symptomatic or uncontrolled brain metastases. * Patients being considered at poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease. * Any psychiatric disorder that prohibits obtaining informed consent * Major surgery or significant traumatic injury within 2 weeks of run-in * Immunocompromised patients * QTc prolongation \>470 msec or other significant ECG abnormality noted within 14 days of treatment * Pregnant and breastfeeding women are excluded. * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) * Previous enrolment in the present study * Participation in a clinical study within 28 days or 5 half-lives of the drug, whichever is longer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm gastric adenocarcinoma gastric cancer gastric neoplasm Her2-receptor negative breast cancer ovarian cancer ovarian disorder small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST Gastric cancers Ovarian SCLC

Contacts and locations

Locations

  • Research Site

    Newnan, Georgia, 30265, United States

  • Research Site

    Towson, Maryland, 21204, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Detroit, Michigan, 48202, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    Hilliard, Ohio, 43026, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Caen, 14076, France

  • Research Site

    Clermont-Ferrand, 63011, France

  • Research Site

    Dijon, 21079, France

  • Research Site

    Marseille, 13385, France

  • Research Site

    Nantes, 44202, France

  • Research Site

    Paris, 75014, France

  • Research Site

    Pierre Benit Cedex, 69495, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Haifa, 91096, Israel

  • Research Site

    Jerusalem, 91031, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Tel Aviv, 6423906, Israel

  • Research Site

    Amsterdam, 1066 CX, Netherlands

  • Research Site

    Amsterdam, 1081 HV, Netherlands

  • Research Site

    Maastricht, 6229 HX, Netherlands

  • Research Site

    Nijmegen, 6525 GA, Netherlands

  • Research Site

    Rotterdam, 3075 EA, Netherlands

  • Research Site

    Utrecht, 3584 CX, Netherlands

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06273, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Seoul, 135-710, South Korea

  • Research Site

    Chur, CH-7000, Switzerland

  • Research Site

    Lausanne, 1011, Switzerland

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    Dundee, DD1 9SY, United Kingdom

  • Research Site

    Glasgow, G12 0YN, United Kingdom

  • Research Site

    Greater London, SW3 6JJ, United Kingdom

  • Research Site

    London, NW1 2PG, United Kingdom

  • Research Site

    London, SE1 9RY, United Kingdom

  • Research Site

    Manchester, M20 4BX, United Kingdom

  • Research Site

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Research Site

    Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.